Mirvetuximab soravtansine (MIRV) is an ADC targeting folate receptor alpha (FRα) that has shown promising efficacy as monotherapy in FRα-positive, platinum-resistant epithelial ovarian cancer (EOC), leading to its accelerated FDA approval. The gene discussed is FOLR1; the disease is ovarian carcinoma.